Global Idiopathic Hypersomnia Treatment Supply, Demand and Key Producers, 2024-2030

Description

The global Idiopathic Hypersomnia Treatment market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Idiopathic hypersomnia (IH) is a rare sleep disorder marked by an over sleeping duration time during the day even after a longer sleeping hours of night sleep. People with idiopathic hypersomnia sleep normal or for long hours each night but still feel excessively sleepy during the day. Idiopathic hypersomnia is a type of hypersomnia and symptoms include chronic excessive daytime sleepiness (EDS), non-refreshing daytime napping, sleep drunkenness after nighttime sleep, naps, and others. Idiopathic hypersomnia is a nervous system disease, whose cause is not known. There is no single drug available that is approved by the U.S. FDA for this disease, but medicines such as dextroamphetamine that are approved for narcolepsy, one of the types of hypersomnia can be used for idiopathic hypersomnia off-label.

This report studies the global Idiopathic Hypersomnia Treatment demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Idiopathic Hypersomnia Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Idiopathic Hypersomnia Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Idiopathic Hypersomnia Treatment total market, 2019-2030, (USD Million)
Global Idiopathic Hypersomnia Treatment total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Idiopathic Hypersomnia Treatment total market, key domestic companies and share, (USD Million)
Global Idiopathic Hypersomnia Treatment revenue by player and market share 2019-2024, (USD Million)
Global Idiopathic Hypersomnia Treatment total market by Type, CAGR, 2019-2030, (USD Million)
Global Idiopathic Hypersomnia Treatment total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Idiopathic Hypersomnia Treatment market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceutical, Teva Pharmaceutical Industries, Jazz Pharmaceuticals, BIOPROJET, Avadel Pharmaceuticals, GlaxoSmithKline, Pfizer, Theranexus and Fisher and Paykel Healthcare, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Idiopathic Hypersomnia Treatment market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Idiopathic Hypersomnia Treatment Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Idiopathic Hypersomnia Treatment Market, Segmentation by Type
    Stimulant Medications
    Non-Stimulant Wake-Promoting Medications
    Sodium Oxybate

Global Idiopathic Hypersomnia Treatment Market, Segmentation by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

Companies Profiled:
    Takeda Pharmaceutical
    Teva Pharmaceutical Industries
    Jazz Pharmaceuticals
    BIOPROJET
    Avadel Pharmaceuticals
    GlaxoSmithKline
    Pfizer
    Theranexus
    Fisher and Paykel Healthcare
    Drive DeVilbiss Healthcare
    Merck

Key Questions Answered
1. How big is the global Idiopathic Hypersomnia Treatment market?
2. What is the demand of the global Idiopathic Hypersomnia Treatment market?
3. What is the year over year growth of the global Idiopathic Hypersomnia Treatment market?
4. What is the total value of the global Idiopathic Hypersomnia Treatment market?
5. Who are the major players in the global Idiopathic Hypersomnia Treatment market?

Table of Contents

1 Supply Summary
    1.1 Idiopathic Hypersomnia Treatment Introduction
    1.2 World Idiopathic Hypersomnia Treatment Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Idiopathic Hypersomnia Treatment Total Market by Region (by Headquarter Location)
        1.3.1 World Idiopathic Hypersomnia Treatment Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Idiopathic Hypersomnia Treatment Market Size (2019-2030)
        1.3.3 China Idiopathic Hypersomnia Treatment Market Size (2019-2030)
        1.3.4 Europe Idiopathic Hypersomnia Treatment Market Size (2019-2030)
        1.3.5 Japan Idiopathic Hypersomnia Treatment Market Size (2019-2030)
        1.3.6 South Korea Idiopathic Hypersomnia Treatment Market Size (2019-2030)
        1.3.7 ASEAN Idiopathic Hypersomnia Treatment Market Size (2019-2030)
        1.3.8 India Idiopathic Hypersomnia Treatment Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Idiopathic Hypersomnia Treatment Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Idiopathic Hypersomnia Treatment Major Market Trends

2 Demand Summary
    2.1 World Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)
    2.2 World Idiopathic Hypersomnia Treatment Consumption Value by Region
        2.2.1 World Idiopathic Hypersomnia Treatment Consumption Value by Region (2019-2024)
        2.2.2 World Idiopathic Hypersomnia Treatment Consumption Value Forecast by Region (2025-2030)
    2.3 United States Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)
    2.4 China Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)
    2.5 Europe Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)
    2.6 Japan Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)
    2.7 South Korea Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)
    2.8 ASEAN Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)
    2.9 India Idiopathic Hypersomnia Treatment Consumption Value (2019-2030)

3 World Idiopathic Hypersomnia Treatment Companies Competitive Analysis
    3.1 World Idiopathic Hypersomnia Treatment Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Idiopathic Hypersomnia Treatment Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Idiopathic Hypersomnia Treatment in 2023
        3.2.3 Global Concentration Ratios (CR8) for Idiopathic Hypersomnia Treatment in 2023
    3.3 Idiopathic Hypersomnia Treatment Company Evaluation Quadrant
    3.4 Idiopathic Hypersomnia Treatment Market: Overall Company Footprint Analysis
        3.4.1 Idiopathic Hypersomnia Treatment Market: Region Footprint
        3.4.2 Idiopathic Hypersomnia Treatment Market: Company Product Type Footprint
        3.4.3 Idiopathic Hypersomnia Treatment Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Idiopathic Hypersomnia Treatment Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Idiopathic Hypersomnia Treatment Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Idiopathic Hypersomnia Treatment Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Idiopathic Hypersomnia Treatment Consumption Value Comparison
        4.2.1 United States VS China: Idiopathic Hypersomnia Treatment Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Idiopathic Hypersomnia Treatment Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Idiopathic Hypersomnia Treatment Companies and Market Share, 2019-2024
        4.3.1 United States Based Idiopathic Hypersomnia Treatment Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Idiopathic Hypersomnia Treatment Revenue, (2019-2024)
    4.4 China Based Companies Idiopathic Hypersomnia Treatment Revenue and Market Share, 2019-2024
        4.4.1 China Based Idiopathic Hypersomnia Treatment Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Idiopathic Hypersomnia Treatment Revenue, (2019-2024)
    4.5 Rest of World Based Idiopathic Hypersomnia Treatment Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Idiopathic Hypersomnia Treatment Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Idiopathic Hypersomnia Treatment Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World Idiopathic Hypersomnia Treatment Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Stimulant Medications
        5.2.2 Non-Stimulant Wake-Promoting Medications
        5.2.3 Sodium Oxybate
    5.3 Market Segment by Type
        5.3.1 World Idiopathic Hypersomnia Treatment Market Size by Type (2019-2024)
        5.3.2 World Idiopathic Hypersomnia Treatment Market Size by Type (2025-2030)
        5.3.3 World Idiopathic Hypersomnia Treatment Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Idiopathic Hypersomnia Treatment Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospital Pharmacies
        6.2.2 Retail Pharmacies
        6.2.3 Online Pharmacies
    6.3 Market Segment by Application
        6.3.1 World Idiopathic Hypersomnia Treatment Market Size by Application (2019-2024)
        6.3.2 World Idiopathic Hypersomnia Treatment Market Size by Application (2025-2030)
        6.3.3 World Idiopathic Hypersomnia Treatment Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Takeda Pharmaceutical
        7.1.1 Takeda Pharmaceutical Details
        7.1.2 Takeda Pharmaceutical Major Business
        7.1.3 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product and Services
        7.1.4 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Takeda Pharmaceutical Recent Developments/Updates
        7.1.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
    7.2 Teva Pharmaceutical Industries
        7.2.1 Teva Pharmaceutical Industries Details
        7.2.2 Teva Pharmaceutical Industries Major Business
        7.2.3 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product and Services
        7.2.4 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Teva Pharmaceutical Industries Recent Developments/Updates
        7.2.6 Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
    7.3 Jazz Pharmaceuticals
        7.3.1 Jazz Pharmaceuticals Details
        7.3.2 Jazz Pharmaceuticals Major Business
        7.3.3 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product and Services
        7.3.4 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Jazz Pharmaceuticals Recent Developments/Updates
        7.3.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
    7.4 BIOPROJET
        7.4.1 BIOPROJET Details
        7.4.2 BIOPROJET Major Business
        7.4.3 BIOPROJET Idiopathic Hypersomnia Treatment Product and Services
        7.4.4 BIOPROJET Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 BIOPROJET Recent Developments/Updates
        7.4.6 BIOPROJET Competitive Strengths & Weaknesses
    7.5 Avadel Pharmaceuticals
        7.5.1 Avadel Pharmaceuticals Details
        7.5.2 Avadel Pharmaceuticals Major Business
        7.5.3 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product and Services
        7.5.4 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Avadel Pharmaceuticals Recent Developments/Updates
        7.5.6 Avadel Pharmaceuticals Competitive Strengths & Weaknesses
    7.6 GlaxoSmithKline
        7.6.1 GlaxoSmithKline Details
        7.6.2 GlaxoSmithKline Major Business
        7.6.3 GlaxoSmithKline Idiopathic Hypersomnia Treatment Product and Services
        7.6.4 GlaxoSmithKline Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 GlaxoSmithKline Recent Developments/Updates
        7.6.6 GlaxoSmithKline Competitive Strengths & Weaknesses
    7.7 Pfizer
        7.7.1 Pfizer Details
        7.7.2 Pfizer Major Business
        7.7.3 Pfizer Idiopathic Hypersomnia Treatment Product and Services
        7.7.4 Pfizer Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Pfizer Recent Developments/Updates
        7.7.6 Pfizer Competitive Strengths & Weaknesses
    7.8 Theranexus
        7.8.1 Theranexus Details
        7.8.2 Theranexus Major Business
        7.8.3 Theranexus Idiopathic Hypersomnia Treatment Product and Services
        7.8.4 Theranexus Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Theranexus Recent Developments/Updates
        7.8.6 Theranexus Competitive Strengths & Weaknesses
    7.9 Fisher and Paykel Healthcare
        7.9.1 Fisher and Paykel Healthcare Details
        7.9.2 Fisher and Paykel Healthcare Major Business
        7.9.3 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product and Services
        7.9.4 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Fisher and Paykel Healthcare Recent Developments/Updates
        7.9.6 Fisher and Paykel Healthcare Competitive Strengths & Weaknesses
    7.10 Drive DeVilbiss Healthcare
        7.10.1 Drive DeVilbiss Healthcare Details
        7.10.2 Drive DeVilbiss Healthcare Major Business
        7.10.3 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product and Services
        7.10.4 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Drive DeVilbiss Healthcare Recent Developments/Updates
        7.10.6 Drive DeVilbiss Healthcare Competitive Strengths & Weaknesses
    7.11 Merck
        7.11.1 Merck Details
        7.11.2 Merck Major Business
        7.11.3 Merck Idiopathic Hypersomnia Treatment Product and Services
        7.11.4 Merck Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Merck Recent Developments/Updates
        7.11.6 Merck Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Idiopathic Hypersomnia Treatment Industry Chain
    8.2 Idiopathic Hypersomnia Treatment Upstream Analysis
    8.3 Idiopathic Hypersomnia Treatment Midstream Analysis
    8.4 Idiopathic Hypersomnia Treatment Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Idiopathic Hypersomnia Treatment Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World Idiopathic Hypersomnia Treatment Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World Idiopathic Hypersomnia Treatment Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World Idiopathic Hypersomnia Treatment Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World Idiopathic Hypersomnia Treatment Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Idiopathic Hypersomnia Treatment Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World Idiopathic Hypersomnia Treatment Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World Idiopathic Hypersomnia Treatment Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World Idiopathic Hypersomnia Treatment Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key Idiopathic Hypersomnia Treatment Players in 2023
    Table 12. World Idiopathic Hypersomnia Treatment Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global Idiopathic Hypersomnia Treatment Company Evaluation Quadrant
    Table 14. Head Office of Key Idiopathic Hypersomnia Treatment Player
    Table 15. Idiopathic Hypersomnia Treatment Market: Company Product Type Footprint
    Table 16. Idiopathic Hypersomnia Treatment Market: Company Product Application Footprint
    Table 17. Idiopathic Hypersomnia Treatment Mergers & Acquisitions Activity
    Table 18. United States VS China Idiopathic Hypersomnia Treatment Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China Idiopathic Hypersomnia Treatment Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based Idiopathic Hypersomnia Treatment Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Idiopathic Hypersomnia Treatment Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies Idiopathic Hypersomnia Treatment Revenue Market Share (2019-2024)
    Table 23. China Based Idiopathic Hypersomnia Treatment Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Idiopathic Hypersomnia Treatment Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies Idiopathic Hypersomnia Treatment Revenue Market Share (2019-2024)
    Table 26. Rest of World Based Idiopathic Hypersomnia Treatment Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Idiopathic Hypersomnia Treatment Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies Idiopathic Hypersomnia Treatment Revenue Market Share (2019-2024)
    Table 29. World Idiopathic Hypersomnia Treatment Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World Idiopathic Hypersomnia Treatment Market Size by Type (2019-2024) & (USD Million)
    Table 31. World Idiopathic Hypersomnia Treatment Market Size by Type (2025-2030) & (USD Million)
    Table 32. World Idiopathic Hypersomnia Treatment Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World Idiopathic Hypersomnia Treatment Market Size by Application (2019-2024) & (USD Million)
    Table 34. World Idiopathic Hypersomnia Treatment Market Size by Application (2025-2030) & (USD Million)
    Table 35. Takeda Pharmaceutical Basic Information, Area Served and Competitors
    Table 36. Takeda Pharmaceutical Major Business
    Table 37. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Product and Services
    Table 38. Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Takeda Pharmaceutical Recent Developments/Updates
    Table 40. Takeda Pharmaceutical Competitive Strengths & Weaknesses
    Table 41. Teva Pharmaceutical Industries Basic Information, Area Served and Competitors
    Table 42. Teva Pharmaceutical Industries Major Business
    Table 43. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Product and Services
    Table 44. Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. Teva Pharmaceutical Industries Recent Developments/Updates
    Table 46. Teva Pharmaceutical Industries Competitive Strengths & Weaknesses
    Table 47. Jazz Pharmaceuticals Basic Information, Area Served and Competitors
    Table 48. Jazz Pharmaceuticals Major Business
    Table 49. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Product and Services
    Table 50. Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. Jazz Pharmaceuticals Recent Developments/Updates
    Table 52. Jazz Pharmaceuticals Competitive Strengths & Weaknesses
    Table 53. BIOPROJET Basic Information, Area Served and Competitors
    Table 54. BIOPROJET Major Business
    Table 55. BIOPROJET Idiopathic Hypersomnia Treatment Product and Services
    Table 56. BIOPROJET Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. BIOPROJET Recent Developments/Updates
    Table 58. BIOPROJET Competitive Strengths & Weaknesses
    Table 59. Avadel Pharmaceuticals Basic Information, Area Served and Competitors
    Table 60. Avadel Pharmaceuticals Major Business
    Table 61. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Product and Services
    Table 62. Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. Avadel Pharmaceuticals Recent Developments/Updates
    Table 64. Avadel Pharmaceuticals Competitive Strengths & Weaknesses
    Table 65. GlaxoSmithKline Basic Information, Area Served and Competitors
    Table 66. GlaxoSmithKline Major Business
    Table 67. GlaxoSmithKline Idiopathic Hypersomnia Treatment Product and Services
    Table 68. GlaxoSmithKline Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 69. GlaxoSmithKline Recent Developments/Updates
    Table 70. GlaxoSmithKline Competitive Strengths & Weaknesses
    Table 71. Pfizer Basic Information, Area Served and Competitors
    Table 72. Pfizer Major Business
    Table 73. Pfizer Idiopathic Hypersomnia Treatment Product and Services
    Table 74. Pfizer Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 75. Pfizer Recent Developments/Updates
    Table 76. Pfizer Competitive Strengths & Weaknesses
    Table 77. Theranexus Basic Information, Area Served and Competitors
    Table 78. Theranexus Major Business
    Table 79. Theranexus Idiopathic Hypersomnia Treatment Product and Services
    Table 80. Theranexus Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 81. Theranexus Recent Developments/Updates
    Table 82. Theranexus Competitive Strengths & Weaknesses
    Table 83. Fisher and Paykel Healthcare Basic Information, Area Served and Competitors
    Table 84. Fisher and Paykel Healthcare Major Business
    Table 85. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Product and Services
    Table 86. Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 87. Fisher and Paykel Healthcare Recent Developments/Updates
    Table 88. Fisher and Paykel Healthcare Competitive Strengths & Weaknesses
    Table 89. Drive DeVilbiss Healthcare Basic Information, Area Served and Competitors
    Table 90. Drive DeVilbiss Healthcare Major Business
    Table 91. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Product and Services
    Table 92. Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 93. Drive DeVilbiss Healthcare Recent Developments/Updates
    Table 94. Merck Basic Information, Area Served and Competitors
    Table 95. Merck Major Business
    Table 96. Merck Idiopathic Hypersomnia Treatment Product and Services
    Table 97. Merck Idiopathic Hypersomnia Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 98. Global Key Players of Idiopathic Hypersomnia Treatment Upstream (Raw Materials)
    Table 99. Idiopathic Hypersomnia Treatment Typical Customers
List of Figure
    Figure 1. Idiopathic Hypersomnia Treatment Picture
    Figure 2. World Idiopathic Hypersomnia Treatment Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Idiopathic Hypersomnia Treatment Total Market Size (2019-2030) & (USD Million)
    Figure 4. World Idiopathic Hypersomnia Treatment Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World Idiopathic Hypersomnia Treatment Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company Idiopathic Hypersomnia Treatment Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company Idiopathic Hypersomnia Treatment Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company Idiopathic Hypersomnia Treatment Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company Idiopathic Hypersomnia Treatment Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company Idiopathic Hypersomnia Treatment Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company Idiopathic Hypersomnia Treatment Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company Idiopathic Hypersomnia Treatment Revenue (2019-2030) & (USD Million)
    Figure 13. Idiopathic Hypersomnia Treatment Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 16. World Idiopathic Hypersomnia Treatment Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 18. China Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 23. India Idiopathic Hypersomnia Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of Idiopathic Hypersomnia Treatment by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Idiopathic Hypersomnia Treatment Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Idiopathic Hypersomnia Treatment Markets in 2023
    Figure 27. United States VS China: Idiopathic Hypersomnia Treatment Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Idiopathic Hypersomnia Treatment Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World Idiopathic Hypersomnia Treatment Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World Idiopathic Hypersomnia Treatment Market Size Market Share by Type in 2023
    Figure 31. Stimulant Medications
    Figure 32. Non-Stimulant Wake-Promoting Medications
    Figure 33. Sodium Oxybate
    Figure 34. World Idiopathic Hypersomnia Treatment Market Size Market Share by Type (2019-2030)
    Figure 35. World Idiopathic Hypersomnia Treatment Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 36. World Idiopathic Hypersomnia Treatment Market Size Market Share by Application in 2023
    Figure 37. Hospital Pharmacies
    Figure 38. Retail Pharmacies
    Figure 39. Online Pharmacies
    Figure 40. Idiopathic Hypersomnia Treatment Industrial Chain
    Figure 41. Methodology
    Figure 42. Research Process and Data Source

Companies Mentioned

Takeda Pharmaceutical
Teva Pharmaceutical Industries
Jazz Pharmaceuticals
BIOPROJET
Avadel Pharmaceuticals
GlaxoSmithKline
Pfizer
Theranexus
Fisher and Paykel Healthcare
Drive DeVilbiss Healthcare
Merck